How are SYRE collar max profit and max loss calculated?

Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the SYRE collar priced from the end-of-day chain at a 30-day expiry (ATM IV 70.90%), the computed maximum profit is $567.50 per contract and the computed maximum loss is -$432.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a SYRE collar?

The breakeven for the SYRE collar priced on this page is roughly $74.33 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SYRE market-implied 1-standard-deviation expected move is approximately 20.33%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current SYRE implied volatility affect this collar?

SYRE ATM IV is at 70.90% with IV rank near 8.69%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

SYRE Collar Strategy

SYRE (Spyre Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

SYRE (Spyre Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.61B, a beta of 3.13 versus the broader market, a 52-week range of 13.93-78.8, average daily share volume of 1.1M, a public-listing history dating back to 2016, approximately 73 full-time employees. These structural characteristics shape how SYRE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 3.13 indicates SYRE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a collar on SYRE?

A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.

Current SYRE snapshot

As of May 15, 2026, spot at $74.25, ATM IV 70.90%, IV rank 8.69%, expected move 20.33%. The collar on SYRE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this collar structure on SYRE specifically: IV regime affects collar pricing on both sides; compressed SYRE IV at 70.90% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 20.33% (roughly $15.09 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SYRE expiries trade a higher absolute premium for lower per-day decay. Position sizing on SYRE should anchor to the underlying notional of $74.25 per share and to the trader's directional view on SYRE stock.

SYRE collar setup

The SYRE collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SYRE near $74.25, the first option leg uses a $80.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SYRE chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SYRE shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 100 shares	Stock	$74.25	long
Sell 1	Call	$80.00	$4.28
Buy 1	Put	$70.00	$4.35

SYRE collar risk and reward

Net Premium / Debit: -$7,432.50
Max Profit (per contract): $567.50
Max Loss (per contract): -$432.50
Breakeven(s): $74.33
Risk / Reward Ratio: 1.312

Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.

SYRE collar payoff curve

Modeled P&L at expiration across a range of underlying prices for the collar on SYRE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	-$432.50
$16.43	-77.9%	-$432.50
$32.84	-55.8%	-$432.50
$49.26	-33.7%	-$432.50
$65.67	-11.6%	-$432.50
$82.09	+10.6%	+$567.50
$98.51	+32.7%	+$567.50
$114.92	+54.8%	+$567.50
$131.34	+76.9%	+$567.50
$147.75	+99.0%	+$567.50

When traders use collar on SYRE

Collars on SYRE hedge an existing long SYRE stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.

SYRE thesis for this collar

The market-implied 1-standard-deviation range for SYRE extends from approximately $59.16 on the downside to $89.34 on the upside. A SYRE collar hedges an existing long SYRE position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current SYRE IV rank near 8.69% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on SYRE at 70.90%. As a Healthcare name, SYRE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SYRE-specific events.

SYRE collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SYRE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SYRE alongside the broader basket even when SYRE-specific fundamentals are unchanged. Always rebuild the position from current SYRE chain quotes before placing a trade.

Frequently asked questions

What is a collar on SYRE?: A collar on SYRE is the collar strategy applied to SYRE (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With SYRE stock trading near $74.25, the strikes shown on this page are snapped to the nearest listed SYRE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are SYRE collar max profit and max loss calculated?: Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the SYRE collar priced from the end-of-day chain at a 30-day expiry (ATM IV 70.90%), the computed maximum profit is $567.50 per contract and the computed maximum loss is -$432.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a SYRE collar?: The breakeven for the SYRE collar priced on this page is roughly $74.33 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SYRE market-implied 1-standard-deviation expected move is approximately 20.33%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a collar on SYRE?: Collars on SYRE hedge an existing long SYRE stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
How does current SYRE implied volatility affect this collar?: SYRE ATM IV is at 70.90% with IV rank near 8.69%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.